<!doctype html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <title>Michael L. Bernauer</title>
        <meta name="description" content="A framework for easily creating beautiful presentations using HTML">
        <meta name="author" content="Michael L. Bernauer">
        <meta name="apple-mobile-web-app-capable" content="yes">
        <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
        <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
        <link rel="stylesheet" href="../reveal/css/reveal.css">
        <link rel="stylesheet" href="../reveal/css/theme/serif.css" id="theme">
        <!-- Code syntax highlighting -->
        <link rel="stylesheet" href="../reveal/lib/css/zenburn.css">
        <!-- Printing and PDF exports -->
        <script>
            var link = document.createElement( 'link' );
            link.rel = 'stylesheet';
            link.type = 'text/css';
            link.href = window.location.search.match( /print-pdf/gi ) ? '../reveal/css/print/pdf.css' : '../reveal/css/print/paper.css';
            document.getElementsByTagName( 'head' )[0].appendChild( link );
        </script>
        <!--[if lt IE 9]>
        <script src="lib/js/html5shiv.js"></script>
        <![endif]-->
    </head>
    <body>

        <div class="reveal">

            <!-- Any section element inside of this container is displayed as a slide -->
            <div class="slides">
<section>
<section data-markdown>
<script type="text/template">
## Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study

<div class="center">Created by [Michael L. Bernauer](http://mlbernauer.com)</div>

<div calss="center">APPE-8: UNMH Internal Medicine - Allison Burnett, PharmD</center>

<div class="center">_January 16, 2016_</div>
</script>
</section>
<section data-markdown>
<script type="text/template">
## Article meta
### Funding
* Boehringer-Ingelheim

### Acceptance date
* October 12, 2015

### Publication date
* November 16, 2015

### Study design:
* Retrospective cohort

### Study site:
* University of Birmingham Centre for Cardiovascular Sciences, Birmingham City Hospital, Birmingham UK
</script>
</section>
</section>
<section data-markdown>
<script type="text/template">
# Background
* Atrial fibrillation is the leading cause of stroke
* Anticoagulation reduces risk of afib associated stroke
* Anticoagulation increases risk for developing bleed
* GI tract is the most common site of bleeding due to oral anticoag treatment in patients with afib
* Little data exist on whether to restart antithrombotic treatment or withold treatment after GI bleed 

<small>1. Needs citation</small>
</script>
</section>
<section data-markdown>
<script type="text/template">
# Objective
>"Examine the risk of all cause mortality and hospital admission or death due to thromoembolism, major bleeding, or recurrent GI bleeding associated with restarting antithrombotic treatment after a GI bleed in patients with atrial fibrillation."
</script>
</section>
<section>
<section data-markdown>
<script type="text/template">
# Methods
</script>
</section>
<section data-markdown>
<script type="text/template">
## Patient registries
* **Danish National Patient Registry**: information on hospital admission data.
    * Primary and secondary diagnoses
    * Procedures and surgical opearations
* **Danish National Prescription Registry**: records all claimed drug prescriptions form pharmacies in Denmark
* **Danish Civil Registration System**: contains information about an individual's vital status and cause of death
</script>
</section>
<section data-markdown>
<script type="text/template">
## Study population
### Inclusion
* Atrial fibrillation
* Experienced GI bleeding while receiving vitamin K antagonist, dabigatran, rivaroxaban, aspirin, clopidogrel, prasugrel, ticagrelor.
* Patients enrolled on first day of discharge following first time admission for GI bleed during period of 1/1/96 to 12/31/12

### Exclusion
* 30 &le; Age &gt; 100
* Valvular heart disease
* Total hip or knee replacement surgery &le; 8 weeks before inclusion event
* DVT or PE &le; 6 months before inclusion event
* Died or experienced thromboembolic event, major bleeding, recurrent GI bleed within 90 days after inclusion event
</script>
</section>
<section data-markdown>
<script type="text/template">
## Antithrombotic treatment
Patients were stratified into groups according to antithrombotic treatment

### Single oral anticoagulant
* Vitamin K antagonist, dabigatran, rivaroxaban

### Single antiplatelet
* Aspirin, clopidogrel, prasugrel, ticagrelor

### Dual or triple therapy
* Oral anticoagulation, aspirin, clopidogrel, prasugrel, ticagrelor
</script>
</section>
<section data-markdown>
<script type="text/template">
## Concomitant medical treatment and comorbidities
### Concomitant meds
* Concomitant medications used during bleeding event were identified using prescription fill history during the 90 days leading up to the inclusion event.
* Concomitant medicaitons used at baseline were determined using prescription fill history during the 90 day blanking peroid

### Comorbidities
* Stroke risk was assessed using CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores
    * CHF, HTN, Age &ge; 75, DM, Stroke or TIA (Vascular disease, Age 65 to 74, Sex[F])
* Bleeding risk was assessed using HAS-BLED
    * HTN, abnormal renal/liver function, stroke, previous bleed, INR, age &ge; 65, drugs (antiplatelet agents, NSAIDs) or EtOH abuse.
</script>
</section>
<section data-markdown>
<script type="text/template">
## Outcomes and follow-up
### Outcomes
* All cause mortality
* Admission to hospital
* Death due to thromboembolism
    * Defined as: ischaemic stroke, transient ischaemic attack, systemic thromboembolism
* Major bleeding
    * Intracranial bleeding, severe bleeding from respiratory system, GI or urinary tract
* Recurrent GI bleeding
    * Defined using all diagnosis codes for GI bleeding

### Follow-up
* Follow up occurred until either of the outcomes: death, five year follow-up, or Dec 31, 2012, whichever came first.
</script>
</section>
<section data-markdown>
<script type="text/template">
## Statistical analysis
* Baseline characteristics were represented using means and standard deviations
* Independence/homogeneity was assessed using &chi;<sup><small>2</small></sup> tests
* Cumulative incidence of outcomes was assessed using the Aalen-Johansen method
* Time dependent Cox proportional hazards models were used to examine the risk of events during follow-up
* Significance was determined using two-sided &alpha; of &lt; 0.05
</script>
</section>
</section>
<section>
<section data-markdown>
<script type="text/template">
# Results
</script>
</section>
<section data-background="flow.png">
</section>
<section data-markdown>
<script type="text/template">
## Outcomes after index bleeding event
| Outcome       | Cumulative indcidence (2yrs)|
| --------------| ----------------------|
| All cause mortality | 39.9% (38.4% to 41.3%, n=1745)         |
| Thromboembolism     | 12.0% (11.0% to 13.0%, n=526)          |
| Major bleeding      | 17.7% (16.5% to 18.8%, n=788)          |
| Recurrent GI bleed  | 12.1% (11.1% to 13.1%, n=526)          |
</script>
</section>
<section data-markdown>
<script type="text/template">
## Baseline study population
* 1,192 patients were excluded during the 90 day blanking peroid
* Baseline population at 90 days post inclusion event consisted of 3,409 patients
* Mean CHAD<sub><small>2</small></sub>DS<sub><small>2</small></sub>-VASc was 3.6 (SD 1.5)
* Mean HAS-BLED was 3.0 (SD 1.0)

| Therapy                                                            | Percent (n)    |
| ------------------------------------------------------------------ | ---------------|
| Single anticoagulant                                               | 21.3% (n=725)  |
| Aspirin                                                            | 35.5% (n=1,212)|
| P2Y<sub><small>12</small></sub> inhibitor                          | 3.0% (n=102)   |
| Anticoagulant + Aspirin                                            | 10.7% (n=363)  |
| Anticoagulant + P2Y<sub><small>12</small></sub> inhibitor          | 0.6% (n=21)    |
| Aspirin + P2Y<sub><small>12</small></sub> inhibitor                | 1.5% (n=51)    |
| Anticoagulant + Aspirin + P2Y<sub><small>12</small></sub> inibitor | 0.3% (n=11)    |
</script>
</section>
<section data-markdown>
<script type="text/template">
## Cumulative indices
* Significant increase in all cause mortality at 5 years in non-resumption and single antiplatelet group
![Cumulative incidence plot](cumplot.png)
![Hazard ratios](hazards.png)
</script>
</section>
<section data-markdown>
<script type="text/template">
## Risk of outcomes associated with antithrombotic treatment after baseline
</script>
</section>
<section data-markdown>
<script type="text/template">
## Concomitant PPI use after GI bleeding
</script>
</section>
<section data-markdown>
<script type="text/template">
## Sensitivity analysis
</script>
</section>
</section>
<section>
<section data-markdown>
<script type="text/template">
# Discussion
</script>
</section>
<section data-markdown>
<script type="text/template">
## GI bleeding as powerful indicator of death
</script>
</section>
<section data-markdown>
<script type="text/template">
## Blanking peroid
</script>
</section>
<section data-markdown>
<script type="text/template">
## Use of PPI inhibitor after GI bleeding
</script>
</section>
<section data-markdown>
<script type="text/template">
## Restart of antithrombotic treatment after recurrent bleeding
</script>
</section>
<section data-markdown>
<script type="text/template">
## Non-vitamin K antagonist oral anticoagulants after GI bleeding
</script>
</section>
<section data-markdown>
<script type="text/template">
## Strengths and limitations
</script>
</section>
</section>

<section data-markdown>
<script type="text/template">
# Conclusion
</script>
</section>
<section data-markdown>
<script type="text/template">
# Author affiliations
* **Gregory Y H Lip**: Bayer, Astellas, Merck, Sanofi, Pfizer/Bristol-Myers Squibb, Daiichi-Sankyo, Biotronik, Medtronic, Portola, **Boehringer Ingelheim**
* **Jonas B Olesen**: Bristol Myers Squibb, **Boehringer Ingelheim**, Lundbeck Foundation, Bristol-Myers Squibb, Capital Region of Denmark, Foundation for Health Research
* **Emil L Fosb&oslash;l**: Janssen Pharmaceuticals, Lundbeck Foundation, Bristol-Meyers Squibb
* **Anna Gundlund**: Bristol-Myeres
* **Gunnar H Gislason**: Pfizer/Bristol-Myers Squibb, Bayer, **Boehringer-Ingelheim**, AstraZeneca

_All authors state independence from the funders_
</script>
</section>
<section data-markdown>
<script type="text/template">
# Citation
1. Staerk L, Lip GY, Olesen JB, Fosb√∏l EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015 Nov 16;351:h5876. doi: 10.1136/bmj.h5876. PubMed PMID: 26572685; PubMed Central PMCID: PMC4646074
</script>
</section>

        </div>
        <script src="../reveal/lib/js/head.min.js"></script>
        <script src="../reveal/js/reveal.js"></script>
        <script>
            // Full list of configuration options available at:
            // https://github.com/hakimel/reveal.js#configuration
            Reveal.initialize({
                controls: true,
                progress: true,
                history: true,
                center: true,
                transition: 'convex', // none/fade/slide/convex/concave/zoom
                // Optional reveal.js plugins
                dependencies: [
                    { src: '../reveal/lib/js/classList.js', condition: function() { return !document.body.classList; } },
                    { src: '../reveal/plugin/markdown/marked.js', condition: function() { return !!document.querySelector( '[data-markdown]' ); } },
                    { src: '../reveal/plugin/markdown/markdown.js', condition: function() { return !!document.querySelector( '[data-markdown]' ); } },
                    { src: '../reveal/plugin/highlight/highlight.js', async: true, condition: function() { return !!document.querySelector( 'pre code' ); }, callback: function() { hljs.initHighlightingOnLoad(); } },
                    { src: '../reveal/plugin/zoom-js/zoom.js', async: true },
                    { src: '../reveal/plugin/notes/notes.js', async: true }
                ]
            });

        </script>
    </body>
</html>
